A new paradigm for topical generic drug products: Impact on therapeutic access

J Am Acad Dermatol. 2020 Jun;82(6):1570-1571. doi: 10.1016/j.jaad.2020.01.062. Epub 2020 Feb 4.

Authors

Sam G Raney¹, Markham C Luke²

Affiliations

¹ Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Electronic address: markham.luke@fda.hhs.gov.

PMID: 32032691
DOI: 10.1016/j.jaad.2020.01.062

No abstract available

Publication types

Editorial

MeSH terms

Administration, Topical
Dermatologic Agents / administration & dosage
Dermatologic Agents / supply & distribution*
Drugs, Generic / administration & dosage
Drugs, Generic / supply & distribution*
Health Services Accessibility / statistics & numerical data*
Humans
United States

Substances

Dermatologic Agents
Drugs, Generic